Cell Therapy Technologies Market by Product (Media, Sera, Reagents, Vessels, Equipment), Process (Expansion, Isolation, Characterization, Collection, Preservation, Distribution, QC), Type (T-cells, Stem Cells), Application (Cancer) - Global Forecast to 20

The global cell therapy technologies market is projected to reach USD 7.91 billion in 2030 from USD 4.41 billion in 2025, with a significant CAGR of 12.4% from 2025 to 2030. The market is experiencing strong growth, driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, along with strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, thereby driving market growth.

“The T-cells segment is projected to record the highest CAGR during the forecast period.”

The cell therapy technologies market is categorized into three primary categories based on cell type: T cells, stem cells, and other cell types. The T-cell segment is expected to grow at the fastest rate during the forecast period, driven by the strong clinical and commercial momentum of CAR-T and TCR therapies in cancer and their expansion into solid tumor indications. Furthermore, increasing regulatory approvals, favorable reimbursement decisions in significant markets, and growing physician familiarity with T-cell immunotherapies are encouraging broader adoption, which in turn boosts demand for specialized media, gene-editing tools, bioreactors, and analytics tailored to T-cell workflows within the cell therapy technology market.

“The cancer application segment accounted for the largest share in 2024.”

The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application segment dominated in 2024 due to the increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and government initiatives are highly supportive, with regulatory approvals facilitating the segment's growth.

“The US dominated the North American cell therapy technologies market in 2024.”

The US is the largest biopharmaceutical market globally and a key hub for cell and gene therapy innovation, making it a core demand center for cell therapy technologies, products, and services. Demand is expected to rise further, supported by a sophisticated research ecosystem, strong venture and public funding, and the presence of foremost CGT technology leaders, including Thermo Fisher Scientific, Danaher, and Merck. The country benefits from substantial NIH and BARDA support for advanced therapies, as well as large precision medicine and population‑scale CGT initiatives run through leading academic and cancer centers. The high uptake of automated cell processing platforms, digital manufacturing, and advanced analytics across clinical and commercial facilities reinforces the US market's leadership. In addition, a mature regulatory framework, robust healthcare infrastructure, and active public–private collaborations continue to foster rapid translation and commercialization of new cell therapy technologies in the US.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market.

Research Coverage:

This research report categorizes the cell therapy technologies market by product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T-cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The report’s scope encompasses detailed information regarding the key factors, including drivers, restraints, challenges, and opportunities, that influence market growth. A thorough analysis of key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, and acquisitions are recent developments in the cell therapy technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (expanding base of approved CGTs and a growing clinical pipeline, growing capital investments in CGT manufacturing capacity, scale-up of allogeneic and iPSC-derived platforms) restraints (high therapy cost and uncertain reimbursement limiting commercial volumes), opportunities (platformized, modular manufacturing solutions for autologous therapies, integration with digital technologies such as AI & ML), and challenges (lack of skilled workforce in CGT manufacturing and automation) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market.
• Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), among others in the market.

Show more